Sign in or create an account to add this stock to your watchlist.
About Novavax (NASDAQ:NVAX)
Novavax, Inc., together with its subsidiary, Novavax AB, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, enhance its specificity to provide protection against related microorganisms, as well as allows immunization with much lower doses of antigen. The company develops respiratory syncytial (RSV) virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III clinical trial; older adults in Phase II clinical trial; and children six months to five years of age in Phase I clinical trial. Novavax, Inc. also develops NanoFlu vaccine, which is in Phase I/II clinical trial for treating seasonal influenza in older adults; and Ebola virus glycoprotein vaccine that is in Phase I clinical trial. Its preclinical programs include Zika virus; combination respiratory vaccine candidate to protect against RSV and seasonal influenza, as well as other infectious disease vaccine candidates. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:NVAX
CUSIP67000210
Phone240-268-2000
Debt
Debt-to-Equity Ratio-3.20
Current Ratio4.03
Quick Ratio4.03
Price-To-Earnings
Trailing P/E Ratio-2.67
Forward P/E Ratio-3.23
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.18 million
Price / Sales20.56
Cash FlowN/A
Price / CashN/A
Book Value($0.26) per share
Price / Book-6.46
Profitability
EPS (Most Recent Fiscal Year)($0.63)
Net Income$-183,760,000.00
Net Margins-529.93%
Return on EquityN/A
Return on Assets-58.74%
Miscellaneous
Employees347
Outstanding Shares381,670,000
Novavax (NASDAQ:NVAX) Frequently Asked Questions
What is Novavax's stock symbol?
Novavax trades on the NASDAQ under the ticker symbol "NVAX."
How were Novavax's earnings last quarter?
Novavax, Inc. (NASDAQ:NVAX) issued its earnings results on Wednesday, May, 9th. The biopharmaceutical company reported ($0.14) EPS for the quarter, missing analysts' consensus estimates of ($0.13) by $0.01. The biopharmaceutical company had revenue of $9.70 million for the quarter, compared to the consensus estimate of $9.33 million. Novavax's revenue for the quarter was up 70.2% compared to the same quarter last year. During the same quarter in the previous year, the business earned ($0.16) earnings per share. View Novavax's Earnings History.
What price target have analysts set for NVAX?
8 equities research analysts have issued 12-month price objectives for Novavax's stock. Their predictions range from $1.35 to $10.00. On average, they anticipate Novavax's stock price to reach $3.5125 in the next year. View Analyst Ratings for Novavax.
What are Wall Street analysts saying about Novavax stock?
Here are some recent quotes from research analysts about Novavax stock:
- 1. According to Zacks Investment Research, "NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants. " (5/15/2018)
- 2. Cantor Fitzgerald analysts commented, "NanoFlu seasonal flu vaccine could be just what the Dr. ordered. The mismatch of commercially available (egg-production-based) seasonal flu vaccines in the current season underscores the theoretical utility of NVAX’s vaccine production technology. Avoiding influenza virus propagation in eggs could reduce the need for egg adaptation and possible generation of virus particles that do not faithfully resemble the wild type viruses recommended by health organizations for inclusion in flu vaccines. Particularly when prevailing strains are highly pathogenic, e.g., H3N2, having a better matched flu vaccine would seem to be desirable, in our view." (3/15/2018)
Are investors shorting Novavax?
Novavax saw a decrease in short interest during the month of May. As of May 15th, there was short interest totalling 50,820,674 shares, a decrease of 3.4% from the April 30th total of 52,587,018 shares. Based on an average trading volume of 4,512,677 shares, the short-interest ratio is currently 11.3 days. Currently, 13.5% of the shares of the stock are short sold.
Who are some of Novavax's key competitors?
Some companies that are related to Novavax include Atara Biotherapeutics (ATRA), Aerie Pharmaceuticals (AERI), Repligen (RGEN), Denali Therapeutics (DNLI), Momenta Pharmaceuticals (MNTA), Editas Medicine (EDIT), Acceleron Pharma (XLRN), Sangamo Therapeutics (SGMO), REGENXBIO (RGNX), Iovance Biotherapeutics (IOVA), Audentes Therapeutics (BOLD), DBV Technologies (DBVT), Cellectis (CLLS), Adaptimmune Therapeutics (ADAP) and Acorda Therapeutics (ACOR).
Who are Novavax's key executives?
Novavax's management team includes the folowing people:
- Mr. Stanley Charles Erck, Pres, CEO & Director (Age 70)
- Mr. John Joseph Trizzino, Sr. VP, Chief Bus. Officer, CFO & Treasurer (Age 58)
- Mr. John A. Herrmann III, Sr. VP, Gen. Counsel & Corp. Sec. (Age 52)
- Dr. Gregory M. Glenn, Pres of R&D (Age 64)
- Ms. Jill Hoyt, VP of HR & Admin.
Has Novavax been receiving favorable news coverage?
News coverage about NVAX stock has been trending somewhat positive on Monday, Accern Sentiment reports. Accern rates the sentiment of news coverage by analyzing more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Novavax earned a daily sentiment score of 0.01 on Accern's scale. They also assigned media stories about the biopharmaceutical company an impact score of 47.39 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
Who are Novavax's major shareholders?
Novavax's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include JPMorgan Chase & Co. (1.86%), Millennium Management LLC (1.39%), Rock Springs Capital Management LP (0.72%), UBS Group AG (0.42%), Schwab Charles Investment Management Inc. (0.40%) and Chicago Equity Partners LLC (0.22%). Company insiders that own Novavax stock include Barclay A Phillips, Gail Boudreaux, Gary C Evans, Gregory M Glenn, James F Young, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Institutional Ownership Trends for Novavax.
Which institutional investors are selling Novavax stock?
NVAX stock was sold by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, JPMorgan Chase & Co., Federated Investors Inc. PA and Chicago Equity Partners LLC. View Insider Buying and Selling for Novavax.
Which institutional investors are buying Novavax stock?
NVAX stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, UBS Group AG, Rock Springs Capital Management LP, Russell Investments Group Ltd., Element Capital Management LLC, Jane Street Group LLC, Cubist Systematic Strategies LLC and Clinton Group Inc.. Company insiders that have bought Novavax stock in the last two years include Barclay A Phillips, Gail Boudreaux, Gregory M Glenn, John A Herrmann III, John Trizzino, Michael A Mcmanus Jr and Stanley C Erck. View Insider Buying and Selling for Novavax.
How do I buy shares of Novavax?
Shares of NVAX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Novavax's stock price today?
One share of NVAX stock can currently be purchased for approximately $1.68.
How big of a company is Novavax?
Novavax has a market capitalization of $641.21 million and generates $31.18 million in revenue each year. The biopharmaceutical company earns $-183,760,000.00 in net income (profit) each year or ($0.63) on an earnings per share basis. Novavax employs 347 workers across the globe.
How can I contact Novavax?
Novavax's mailing address is 20 FIRSTFIELD ROAD, GAITHERSBURG MD, 20878. The biopharmaceutical company can be reached via phone at 240-268-2000 or via email at [email protected]
MarketBeat Community Rating for Novavax (NVAX)
MarketBeat's community ratings are surveys of what our community members think about Novavax and other stocks. Vote "Outperform" if you believe NVAX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVAX will underperform the S&P 500 over the long term. You may vote once every thirty days.
Novavax (NASDAQ:NVAX) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
8 Wall Street analysts have issued ratings and price targets for Novavax in the last 12 months. Their average twelve-month price target is $3.5125, suggesting that the stock has a possible upside of 109.08%. The high price target for NVAX is $10.00 and the low price target for NVAX is $1.35. There are currently 1 sell rating, 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus rating of "Hold."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Hold | Hold | Hold | Hold |
| Consensus Rating Score: | 2.38 | 2.38 | 2.29 | 2.43 |
| Ratings Breakdown: | 1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 1 Sell Rating(s)
3 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
5 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $3.5125 | $3.5125 | $3.0857 | $3.4333 |
| Price Target Upside: | 109.08% upside | 97.33% upside | 27.51% upside | 201.17% upside |
Novavax (NASDAQ:NVAX) Consensus Price Target History
Novavax (NASDAQ:NVAX) Analyst Ratings History
Show:
(Data available from 5/28/2016 forward)
Novavax (NASDAQ:NVAX) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Novavax (NASDAQ NVAX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.00%
Institutional Ownership Percentage: 40.12%
Novavax (NASDAQ NVAX) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/14/2018 | John Trizzino | SVP | Buy | 50,000 | $1.64 | $82,000.00 | 138,965 |  |
| 5/14/2018 | Stanley C Erck | Insider | Buy | 100,000 | $1.65 | $165,000.00 | 328,279 | |
| 1/31/2018 | Gregory M. Glenn | Insider | Buy | 12,784 | $0.88 | $11,249.92 | | |
| 11/9/2017 | Stanley C Erck | Insider | Buy | 100,000 | $1.13 | $113,000.00 | 228,279 | |
| 8/31/2017 | James F. Young | Director | Sell | 175,000 | $1.06 | $185,500.00 | | |
| 7/31/2017 | Barclay A. Phillips | CFO | Buy | 2,057 | $0.89 | $1,830.73 | | |
| 5/12/2017 | Michael A Mcmanus Jr | Director | Buy | 20,000 | $0.97 | $19,400.00 | 277,590 | |
| 5/11/2017 | Barclay A Phillips | CFO | Buy | 25,000 | $0.84 | $21,000.00 | 36,612 | |
| 5/11/2017 | Michael A Mcmanus Jr | Director | Buy | 10,000 | $0.84 | $8,400.00 | 257,590 | |
| 5/11/2017 | Stanley C Erck | Insider | Buy | 50,000 | $0.84 | $42,000.00 | 128,279 | |
| 1/31/2017 | Barclay A. Phillips | CFO | Buy | 1,633 | $1.12 | $1,828.96 | | |
| 1/31/2017 | John A. Herrmann III | SVP | Buy | 4,960 | $1.12 | $5,555.20 | | |
| 12/7/2016 | Gregory M Glenn | Insider | Buy | 1,000 | $1.45 | $1,450.00 | 4,427 | |
| 9/22/2016 | John Trizzino | SVP | Buy | 46,000 | $2.17 | $99,820.00 | 85,564 | |
| 9/21/2016 | Gregory M Glenn | Insider | Buy | 1,000 | $1.65 | $1,650.00 | 3,427 | |
| 9/21/2016 | Michael A Mcmanus Jr | Director | Buy | 30,000 | $1.61 | $48,300.00 | 247,590 | |
| 9/20/2016 | Gail Boudreaux | Director | Buy | 100,000 | $1.45 | $145,000.00 | 200,000 | |
| 7/31/2016 | Barclay A. Phillips | CFO | Buy | 422 | $4.29 | $1,810.38 | | |
| 6/6/2016 | Gary C Evans | Director | Sell | 18,998 | $6.50 | $123,487.00 | 321,979 | |
| 5/24/2016 | Gary C Evans | Director | Sell | 50,000 | $5.41 | $270,500.00 | 357,111 | |
| 3/31/2016 | Stanley C Erck | CEO | Sell | 424,778 | $5.19 | $2,204,597.82 | 301,066 | |
| 1/31/2016 | Barclay A. Phillips | CFO | Buy | 405 | $4.38 | $1,773.90 | | |
| 1/31/2016 | Gregory M. Glenn | SVP | Buy | 2,369 | $4.38 | $10,376.22 | | |
| 1/31/2016 | Stanley C. Erck | CEO | Buy | 2,072 | $4.38 | $9,075.36 | | |
| 12/16/2015 | John A Herrmann III | SVP | Sell | 27,945 | $8.64 | $241,444.80 | 40 | |
| 8/24/2015 | Gary C Evans | Director | Sell | 20,000 | $11.24 | $224,800.00 | 340,977 | |
| 8/20/2015 | Barclay A. Phillips | CFO | Sell | 28,656 | $13.06 | $374,247.36 | 9,152 | |
| 8/18/2015 | Gregory M. Glenn | SVP | Sell | 15,000 | $13.52 | $202,800.00 | 1,158 | |
| 8/13/2015 | Gary C Evans | Director | Sell | 6,002 | $13.56 | $81,387.12 | | |
| 6/18/2015 | James F Young | Director | Sell | 50,000 | $9.47 | $473,500.00 | | |
| 6/17/2015 | Rajiv I Modi | Director | Sell | 433,053 | $9.01 | $3,901,807.53 | | |
| 6/11/2015 | Rajiv I Modi | Director | Sell | 11,185 | $9.00 | $100,665.00 | | |
| 6/10/2015 | Rajiv I Modi | Director | Sell | 551,081 | $8.97 | $4,943,196.57 | | |
| 6/9/2015 | Rajiv I Modi | Director | Sell | 47,531 | $8.93 | $424,451.83 | | |
| 6/8/2015 | Rajiv I Modi | Director | Sell | 206,175 | $8.93 | $1,841,142.75 | | |
| 6/4/2015 | Rajiv I Modi | Director | Sell | 504,681 | $8.92 | $4,501,754.52 | | |
| 6/1/2015 | Rajiv I Modi | Director | Sell | 3,500,000 | $8.74 | $30,590,000.00 | | |
| 1/31/2015 | Barclay A Phillips | CFO | Buy | 8,388 | $2.28 | $19,124.64 | | |
| 1/31/2015 | John Trizzino | SVP | Buy | 6,611 | $3.63 | $23,997.93 | | |
| 1/31/2015 | Stanley C Erck | CEO | Buy | 6,122 | $2.28 | $13,958.16 | | |
| 12/16/2014 | Gary C Evans | Director | Sell | 46,701 | $5.72 | $267,129.72 | | |
| 12/12/2014 | Gary C Evans | Director | Sell | 30,000 | $5.77 | $173,100.00 | | |
| 11/20/2014 | Rajiv I Modi | Director | Sell | 518,889 | $5.02 | $2,604,822.78 | | |
| 11/18/2014 | Rajiv I Modi | Director | Sell | 1,481,111 | $5.00 | $7,405,555.00 | | |
| 10/3/2014 | Barclay A Phillips | CFO | Buy | 5,000 | $4.11 | $20,550.00 | | |
| 10/3/2014 | Timothy Jon Hahn | SVP | Buy | 2,500 | $4.05 | $10,125.00 | | |
| 9/26/2014 | Gregory M Glenn | SVP | Sell | 16,809 | $4.16 | $69,925.44 | | |
| 9/25/2014 | Timothy Jon Hahn | SVP | Buy | 9,000 | $4.17 | $37,530.00 | | |
| 7/31/2014 | Barclay A Phillips | CFO | Buy | 8,788 | $2.28 | $20,036.64 | | |
| 7/31/2014 | Russell P Wilson | SVP | Buy | 4,989 | $2.28 | $11,374.92 | | |
| 7/31/2014 | Stanley C Erck | CEO | Buy | 6,788 | $2.28 | $15,476.64 | | |
| 6/17/2014 | John Trizzino | SVP | Buy | 5,500 | $4.51 | $24,805.00 | | |
| 6/16/2014 | John Trizzino | SVP | Buy | 16,500 | $4.51 | $74,415.00 | | |
| 3/25/2014 | Barclay Phillips | CFO | Buy | 5,000 | $4.25 | $21,250.00 | 14,868 | |
| 3/25/2014 | Richard Douglas | Director | Buy | 50,000 | $4.33 | $216,500.00 | 250,000 | |
| 3/25/2014 | Stanley Erck | CEO | Buy | 10,000 | $4.27 | $42,700.00 | 84,868 | |
| 3/21/2014 | Pharmaceuticals Ltd Cadila | major shareholder | Sell | 3,000,000 | $4.95 | $14,850,000.00 | | |
| 1/31/2014 | Barclay Phillips | CFO | Buy | 9,868 | $2.29 | $22,597.72 | 9,868 | |
| 1/31/2014 | Stanley Erck | CEO | Buy | 11,868 | $2.29 | $27,177.72 | 74,868 | |
| 1/31/2014 | Timothy Jon Hahn | SVP | Buy | 9,416 | $2.29 | $21,562.64 | 80,416 | |
| 6/12/2013 | Richard Douglas | Director | Buy | 50,000 | $1.90 | $95,000.00 | | |
| 6/10/2013 | Timothy Jon Hahn | SVP | Buy | 21,000 | $1.88 | $39,480.00 | | |
| 6/7/2013 | Gregory M Glenn | Insider | Buy | 2,000 | $1.92 | $3,840.00 | | |
| 6/6/2013 | James F Young | Director | Buy | 100,000 | $1.91 | $191,000.00 | | |
| 3/11/2013 | James F Young | Director | Buy | 100,000 | $2.03 | $203,000.00 | | |
(Data available from 1/1/2013 forward)
Novavax (NASDAQ NVAX) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Novavax, Inc. (NVAX) Short Interest Down 3.4% in May
www.americanbankingnews.com - May 28 at 1:20 AM |
| Novavax, Inc. (NVAX) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 24 at 3:34 PM |
| Cantor Fitzgerald Brokers Lift Earnings Estimates for Novavax, Inc. (NVAX)
www.americanbankingnews.com - May 24 at 8:34 AM |
 | Novavax: All Eyes On Q1 2019
seekingalpha.com - May 23 at 8:00 AM |
| Novavax (NVAX) versus CRISPR Therapeutics (CRSP) Critical Comparison
www.americanbankingnews.com - May 22 at 11:08 PM |
 | Free Technical Insights on OPKO Health and Three Other Biotech Stocks
finance.yahoo.com - May 22 at 8:03 AM |
| Brokers Issue Forecasts for Novavax's Q2 2018 Earnings (NVAX)
www.americanbankingnews.com - May 18 at 7:09 AM |
| FY2021 Earnings Estimate for Novavax (NVAX) Issued By B. Riley
www.americanbankingnews.com - May 17 at 9:10 AM |
| Novavax up 3% premarket
seekingalpha.com - May 16 at 9:18 AM |
 | Form 4 NOVAVAX INC For: May 14 Filed by: Erck Stanley C
www.streetinsider.com - May 15 at 5:31 PM |
| Form 4 NOVAVAX INC For: May 14 Filed by: Glenn Gregory M
www.streetinsider.com - May 15 at 5:31 PM |
| John Trizzino Purchases 50,000 Shares of Novavax (NVAX) Stock
www.americanbankingnews.com - May 15 at 4:43 PM |
| Insider Buying: Novavax (NVAX) Insider Acquires 100,000 Shares of Stock
www.americanbankingnews.com - May 15 at 4:18 PM |
| Zacks Investment Research Lowers Novavax (NVAX) to Hold
www.americanbankingnews.com - May 15 at 11:51 AM |
| Novavax Forecasted to Post Q2 2018 Earnings of ($0.12) Per Share (NVAX)
www.americanbankingnews.com - May 14 at 2:00 AM |
| Zacks: Analysts Expect Novavax (NVAX) Will Announce Quarterly Sales of $9.93 Million
www.americanbankingnews.com - May 13 at 4:34 AM |
| Short Interest in Novavax (NVAX) Declines By 3.8%
www.americanbankingnews.com - May 12 at 2:11 AM |
| Zacks: Brokerages Expect Novavax (NVAX) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - May 11 at 12:26 PM |
| Novavax's (NVAX) CEO Stanley Erck on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 10 at 8:33 AM |
| Edited Transcript of NVAX earnings conference call or presentation 9-May-18 8:30pm GMT
finance.yahoo.com - May 10 at 8:33 AM |
| Novavax: 1Q Earnings Snapshot
finance.yahoo.com - May 10 at 8:33 AM |
| Novavax (NVAX) Releases Earnings Results, Misses Estimates By $0.01 EPS
www.americanbankingnews.com - May 9 at 9:14 PM |
| Novavax Reports First Quarter 2018 Financial Results
finance.yahoo.com - May 9 at 5:25 PM |
 | Why Novavax, Inc. Stock Plunged Last Month
www.fool.com - May 7 at 12:30 PM |
 | Novavax Reaches Significant Enrollment Milestone in the Prep
www.lse.co.uk - May 7 at 9:21 AM |
 | BRIEF-Novavax Says Topline Efficacy Data From Prepare Phase 3 Clinical Trial Expected In Q1 Of 2019
www.reuters.com - May 7 at 9:21 AM |
| Will Novavax Inc’s (NASDAQ:NVAX) Earnings Grow In The Years Ahead?
finance.yahoo.com - May 6 at 8:34 AM |
| Analyzing Bavarian Nordic (BVNRY) and Novavax (NVAX)
www.americanbankingnews.com - May 6 at 5:09 AM |
| Novavax (NVAX) Lifted to "Sell" at ValuEngine
www.americanbankingnews.com - May 2 at 11:06 PM |
| The Time Is Right To Buy Novavax
seekingalpha.com - May 2 at 5:23 PM |
| Novavax to Host Conference Call to Discuss First Quarter Financial Results on May 9, 2018
finance.yahoo.com - May 2 at 5:22 PM |
| Novavax (NVAX) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 29 at 3:30 PM |
| Novavax (NVAX) Sees Significant Drop in Short Interest
www.americanbankingnews.com - April 27 at 4:08 AM |
| Has Novavax (NVAX) Outpaced Other Medical Stocks This Year?
finance.yahoo.com - April 26 at 5:19 PM |
| BidaskClub Downgrades Novavax (NVAX) to Hold
www.americanbankingnews.com - April 26 at 1:14 PM |
| $9.25 Million in Sales Expected for Novavax (NVAX) This Quarter
www.americanbankingnews.com - April 25 at 1:52 AM |
| -$0.14 Earnings Per Share Expected for Novavax (NVAX) This Quarter
www.americanbankingnews.com - April 23 at 11:10 PM |
| Don't Get Greedy With Novavax, Inc. Stock
www.fool.com - April 23 at 5:16 PM |
| Q2 2018 Earnings Estimate for Novavax Issued By Piper Jaffray (NVAX)
www.americanbankingnews.com - April 19 at 6:26 AM |
 | Free Research Reports on These Biotech Stocks -- Moleculin Biotech, MyoKardia, Nektar Therapeutics, and Novavax
www.prnewswire.com - April 18 at 8:44 AM |
| Novavax (NVAX) Downgraded by BidaskClub to "Sell"
www.americanbankingnews.com - April 17 at 1:54 PM |
| Novavax (NVAX) Price Target Lowered to $2.00 at Piper Jaffray
www.americanbankingnews.com - April 17 at 8:27 AM |
| Buy Novavax After Its Latest Pullback?
finance.yahoo.com - April 17 at 8:25 AM |
| Novavax Announces Closing of Public Offering
finance.yahoo.com - April 16 at 5:29 PM |
| Piper Jaffray Reiterates "Hold" Rating for Novavax (NVAX)
www.americanbankingnews.com - April 15 at 11:42 PM |
| Novavax (NVAX) Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - April 15 at 11:11 PM |
| Novavax (NVAX) Earns Neutral Rating from Chardan Capital
www.americanbankingnews.com - April 15 at 2:21 PM |
| Novavax (NVAX) Upgraded by BidaskClub to Hold
www.americanbankingnews.com - April 15 at 12:35 PM |
| Novavax, Inc.
www.streetinsider.com - April 13 at 5:26 PM |
| Today’s Research Reports on Stocks to Watch: Novavax and Pfizer
finance.yahoo.com - April 13 at 8:32 AM |
Novavax (NASDAQ:NVAX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Novavax (NASDAQ:NVAX) Income Statement, Balance Sheet and Cash Flow Statement
Novavax (NASDAQ NVAX) Stock Chart for Monday, May, 28, 2018
Loading chart…
